PT - JOURNAL ARTICLE AU - Ajaz, Sadia AU - Zaidi, Sani-e-Zehra AU - Ali, Saleema Mehboob AU - Siddiqa, Aisha AU - Memon, Muhammad Ali AU - Abid, Aiysha AU - Khaliq, Shagufta TI - Independent and Combined Associations of 677C/T and 1298A/C Polymorphisms in the <em>MTHFR</em> gene with Breast Cancers in a South-Asian Population AID - 10.1101/2021.03.13.21253512 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.13.21253512 4099 - http://medrxiv.org/content/early/2021/03/13/2021.03.13.21253512.short 4100 - http://medrxiv.org/content/early/2021/03/13/2021.03.13.21253512.full AB - MTHFR is a pivotal enzyme in the folic acid cycle. Two functional SNPs (677C/T and 1298A/C), which affect the function of the MTHFR, are associated with different cancers. In the present study, these SNPs were investigated in breast cancer patients from the Pakistani population. The pilot study includes 187 participants with 124 breast cancer patients and 63 medically confirmed healthy individuals as controls. PCR-RFLP methods validated by Sanger sequencing were used for the polymorphic investigations. Here, we report the significant and unique associations of these polymorphisms with breast cancers in a South-Asian population for the first time in the literature. The case-control analysis showed that in case of 1298A/C polymorphism, a significant protective effect of homozygous C genotype was observed in recessive [CC vs AA+AC; OR: 0.320 (95% CI: 0.259 – 0.397)] and homozygous co-dominant [CC vs AA; OR 0.379 (95% CI: 0.273 – 0.527)] models. In the case of 677C/T analysis, no significant association was observed with the risk of breast cancers. However, homozygous T genotype was more frequent in the advanced age group (&gt;35 years) patients as compared to the young age-group (&lt;35 years) i.e. 6.7% vs 0%. The combined genotype analysis at two loci revealed that 677CC+1298AC [OR: 2.688 (95% CI: 1.247-5.795)] and 677CT+1298AA [OR.:20.91 (95% CI: 1.156-378.2)] increased risk of breast cancers, significantly. The latter association (677T*1298A) was also observed in a semi-parametric haplotype analysis (p-value: 0.03). The study indicates translational applications of these polymorphisms against breast cancers in the studied population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementPakistan Health Research Council (Ref. No. S-7/17/RDC/UOK/1383 (Received: USD 78)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the ethical review committees (ERCs) of the participating institutions: the independent ERC, International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi, Pakistan [ICCBS/IEC-016-BS/HT-2016/Protocol/1.0], and the Atomic Energy Medical Centre (AEMC), Jinnah Postgraduate Medical Centre (JPMC), Karachi, Pakistan [Admin-3(257)/2016]All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request